Evidence map›Paper›PMID 40464925›Full record

ArticleSurgery today2025

PD-L1 expression correlates with the oncological severity and prognosis of early-stage lung cancer.

Ken Onodera, Hirotsugu Notsuda, Sakiko Kumata, Tatsuaki Watanabe, Yui Watanabe, Takaya Suzuki, Takashi Hirama, Hisashi Oishi, Yoshinori Okada

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ken OnoderaDepartment of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Seiryomachi 4-1, Aoba-ku, Sendai, Miyagi, 980-8575, Japan. ken.onodera.c3@tohoku.ac.jp.ORCID http://orcid.org/0000-0002-2571-8815
Hirotsugu NotsudaDepartment of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Seiryomachi 4-1, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Sakiko KumataDepartment of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Seiryomachi 4-1, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Tatsuaki WatanabeDepartment of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Seiryomachi 4-1, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Yui WatanabeDepartment of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Seiryomachi 4-1, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Takaya SuzukiDepartment of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Seiryomachi 4-1, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Takashi HiramaDepartment of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Seiryomachi 4-1, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Hisashi OishiDepartment of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Seiryomachi 4-1, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Yoshinori OkadaDepartment of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Seiryomachi 4-1, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe expression of PD-L1 is linked to lung cancer severity; however, its prognostic value after resection is unclear. In this study, we investigated its role in resected lung cancers.

methodsWe analyzed 658 patients with stage pIA-IIIA NSCLC who underwent complete resection. We assessed the PD-L1 expression by stage and its link to cancer severity, focusing further on its prognostic impact in resected stage I cell lung cancer.

resultsThe high expression of PD-L1 increased with disease progression (13.0% in IA to 36.2% in III). In stage I non-small cell lung cancer, elevated PD-L1 expression levels were more common in patients with serum CEA levels ≥ 5 (26.0%), SUVmax ≥ 5 (26.7%), and squamous cell carcinoma (41.5%). PD-L1-negative patients showed a better prognosis than PD-L1-positive patients, even with the use of immune checkpoint inhibitors following relapse (5-year OS: 94.3% vs. 83.2%, p < 0.01).

conclusionThe expression of PD-L1 in lung cancer appears to be associated with oncological severity and may influence the prognosis of early-stage disease. Additionally, in early-stage lung cancer, immune checkpoint inhibitors may not fully compensate for the negative prognostic impact of the high expression of PD-L1.

Indexed as

B7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungGene ExpressionLung NeoplasmsAdultAgedAged, 80 and overDisease ProgressionFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisSeverity of Illness IndexB7-H1 AntigenBiomarkers, TumorCD274 protein, humanExpressionLung cancerMalignancyNSCLCPD-L1

Identifiers

PMID40464925
PMCPMC12534232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.